Drug | Company Stocks To Buy

: Over 70 high-revenue drugs face patent expirations by 2026, which Morningstar reports predict will trigger major mergers and acquisitions (M&A) as companies race to backfill assets.

: Listed as one of the best pharmaceutical dividend stocks for 2026, showing steady clinical progress and outperforming the broader market. drug company stocks to buy

: Identified by Barclays as a value play for 2026 due to its solid pipeline and high dividend yield, despite near-term patent expirations. : Over 70 high-revenue drugs face patent expirations

Best Pharmaceutical Stocks for 2026 and How to Invest in Them Best Pharmaceutical Stocks for 2026 and How to

For April 2026, analysts highlight a mix of high-growth biotech and established pharmaceutical companies with strong pipelines in obesity, oncology, and rare diseases. Leading research reports categorize top picks based on market stability and innovation potential.

: Performance in 2026 is expected to be bolstered by clearer U.S. drug pricing and tariff policies, as noted in Morningstar's sector outlook .

: A high-growth pick frequently highlighted in Zacks reports for its significant projected sales growth (over 20%) and low forward PE ratio. Key Market Drivers & Sector Outlook